Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Bright Minds Biosciences Inc
C.DRUG
Alternate Symbol(s):
DRUG
Healthcare
Biotechnology
Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy and pain. The Company has a portfolio of serotonin agonists designed to target neurocircuit abnormalities to treat disorders, such as resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain...
. It is focused on developing a line of serotonergic 5-Hydroxytryptamine (5-HT) drug candidates that target the 5-HT2C, 5-HT2A and 5-HT2A + 5-HT2C receptors. Its offers 5-HT2C for the treatment of dravet syndrome and behavioral disorders. Its offers 5-HT2A for treatment of depression and other neuropsychiatric disorders. The Company offers 5-HT2A + 5-HT2C for several chronic pain disorders/neuropathic pain syndromes, including cluster headaches and chemotherapy-induced peripheral neuropathy.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (CSE:DRUG)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
Next
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Aug 08, 2023 1:49pm
DRUG...it's all about the money Honey
Huge waterfall after the "blowoff"....when the P.O announcement???? Sheeeesh !!!!!!!!!!!!!!!
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 17, 2023 2:43pm
DRUG ....scalped
on the move
Additional Drill Results from Phase 1 Program & Plans for Phase II Exploration
posted Dec 01, 2023 9:00am by
Heritage Mining Ltd.
-
|
Our 2023 field and drill program has not only validated but also expanded the deformation corridor, now boasting an impressive ~200m width, 1km in strike length and a depth reaching at least 145m, which remains wide open in all directions. Against the backdrop of a robust gold environment, we are delighted to announce plans for Phase II at Alcona ...read more
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 14, 2023 1:02pm
DRUG.... Bleeding like a stuffed pig
What else Go do some more drugs ; )
(63)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 14, 2023 11:34am
DRUG ..... 5 : 1 RS this a.m
Let it bleed
(1)
•••
OTCLegenda
X
Post by
OTCLegenda
on Sep 19, 2022 1:51pm
There’s been a lot of buzz about psychedelic stocks lately
DRUG has actually kept the gains it made on its mid-August sympathy run. The psychedelic sector hasn’t caught fire like marijuana and biotechs have in the past couple years.
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 07, 2022 6:50am
New Press Release - Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATESVANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the...
read article.
(433)
•••
AwareInvestor
X
Post by
AwareInvestor
on Aug 31, 2022 8:54am
Bright Minds Begins Phase 1 Clinical Trials Focused On Treat
Phase 1 trials are officially underway for Bright Minds Biosciences and their lead product, referred to as BMB-101. The firm this morning revealed that it has dosed the first patient under the trial
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 31, 2022 6:50am
New Press Release - Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome
In predictive animal models, BMB-101 demonstrated significant reduction in both the number and intensity of epileptic seizures VANCOUVER, British Columbia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 30, 2022 3:35pm
New Press Release - Bright Minds Biosciences Announces Closing of $4 Million Unit Offering
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.VANCOUVER, British Columbia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (...
read article.
(433)
•••
AwareInvestor
X
Post by
AwareInvestor
on Aug 24, 2022 8:41am
Bright Minds Biosciences Looks To Raise $4.0 Million Via Ove
After several days of intense volatility, Bright Minds Biosciences is looking to capitalize on the sudden investor interest. The firm has now announced terms for the pricing of its overnight marketed
...more
(40)
•••
cueball40
X
Post by
cueball40
on Aug 19, 2022 11:09am
im in
trying 5k here 2.17 area let her rip
(16)
•••
hashboy18
X
Post by
hashboy18
on Aug 18, 2022 1:08pm
shorts get smoked
they shorted it too low and got greedy,huge.ca is also short 6,2 million anson is feeling pain today
(4)
•••
Whitman19
X
Post by
Whitman19
on Apr 13, 2022 2:52am
Upcoming catalysts
The next couple of catalysts include the toxicology study for 5HT2A to treat MDD/TRD and the Phase-1 clinical trials for BMB-101 to treat Alzheimer's. Both are likely to start this quarter
(4)
•••
Whitman19
X
Comment by
Whitman19
on Mar 25, 2022 2:59am
RE:Bright Minds Moves Into Clinical Development Stage Following
That's wonderful. Just waiting for the stock to take off
(433)
•••
AwareInvestor
X
Post by
AwareInvestor
on Mar 14, 2022 7:55am
Bright Minds Moves Into Clinical Development Stage Following
Drug development continues for the Bright Minds Biosciences lead product. The firm this morning published positive results from a recent 28-day toxicity study conducted on its novel formulation, BMB
...more
Prev
1
2
3
4
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Pulsar Helium to Present and Host Open Q&A at the Emerging Growth Conference Dec. 7 – Register Now
AI Beyond Hype: Real-world Applications and Possibilities
Gander Gold Discovers Significant Gold System at Lizard Pond Claims – Gander South Project